U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

(220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.

  • Product Code
  • ILEA000954516
  • Registered date
  • 2022/4/15 00:00:00
  • Credit
  • Xinhua / Kyodo News Images
  • Media source
  • Xinhua News Agency.All Rights Reserved
  • Media size
  • 2618 × 1867 pixel
  • Resolution
  • dpi
  • Deployment size
  • 695.14(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

    U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

    (220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.
      U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

      U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

      (220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.